This article will reflect on the compensation paid to Chris Linthwaite who has served as CEO of Fluidigm Corporation…

from Yahoo Finance https://ift.tt/32n2xvR

Guru ups bet in biotech focused on ear-related disorders Continue reading…

from Yahoo Finance https://ift.tt/2WoKWQt

Does the July share price for United Parcel Service, Inc. (NYSE:UPS) reflect what it's really worth? Today, we will…

from Yahoo Finance https://ift.tt/2OrIJiP

Yahoo Finance’s On the Move panel breaks down the latest news stories in ‘News on the Move’.

from Yahoo Finance https://ift.tt/3h5XNz9

On July 8, 2020, Giverny Capital released its Q2 2020 Investor Letter, a copy of which you can download here. The Fund returned 19.64% for the second quarter of 2020. Meanwhile, the benchmark S&P 500 Index gained 20.54%. You should check out Giverny Capital's top 5 stock picks for investors to buy right now, which could […]

from Yahoo Finance https://ift.tt/3h0Hp2M

from Yahoo Finance https://ift.tt/2Wl4yF8

On July 14, 2020, Silver Ring Value Partners LP released its Q2 2020 Investor Letter, a copy of which you can download here. The investment firm was founded in 2016 by Chief Investment Officer and Managing Partner Gary Mishuris. In its Q2 2020 Investor Letter, Silver Ring Value Partners LP reported 14 investments with a […]

from Yahoo Finance https://ift.tt/307uUvu

AbbVie Inc (NYSE: ABBV) shares popped Tuesday after researchers found that the large-cap pharma's cholesterol-lowering drug Tricor could work against SARS-CoV2, the virus that causes COVID-19.What Happened: Researchers at Israel's Hebrew University and the Mount Sinai Medical Center in New York said FDA-approved Tricor could potentially downgrade COVID-19's severity into "nothing worse than a common cold," Israeli media reported.Tricor impairs the replicating potential of the new coronavirus or even could eradicate it, the reports said, citing Hebrew University professor Ya'acov Nahmias and Sinai's Dr. Benjamin tenOever.See Also: Moderna's Stock Jumps After Coronavirus Vaccine Shows Positive Results In Phase 1 Clinical TrialHow Tricor Acts: Following three months of in vitro, or lab, studies and a review of eight already approved drugs, the researchers found that Tricor burns fat, causing the virus to disappear with merely five days of treatment.SARS-Co-V2 was found to impede with the carbohydrate metabolism, leading to the accumulation of fat inside the lung cells, which in turn provides a conducive environment for the thriving of the virus.Tricor's fat-burning mechanism comes in handy to make the environment inclement for the virus, leading to its eventual elimination, studies found.What's Next? The researchers are advancing the drug into animal studies in the U.S. With the safety of Tricor already proved, they hope to fast track clinical studies both in the U.S. and Israel within the next couple of weeks.After advancing 2.27% to $98.87 in Tuesday's session, AbbVie shares were up 0.95% to $99.81 on Wednesday morning.See more from Benzinga * The Daily Biotech Pulse: Ziopharm Starts Blood Cancer Study, Allergan's Botox Gets Label Expansion, 3 IPOs * The Daily Biotech Pulse: Intersect ENT Jumps On M&A Speculation, VIVUS Files For Bankruptcy * The Daily Biotech Pulse: Novartis Settles Lawsuit For 8M, Sarepta In-Licenses Gene Therapy Pre-Treatment, Unity Biotech Outlines Second-Half Catalysts(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

from Yahoo Finance https://ift.tt/2ZsEudg

While it may not be enough for some shareholders, we think it is good to see the Chimera Investment Corporation…

from Yahoo Finance https://ift.tt/32lkFXe

Moderna’s (MRNA)’s experimental coronavirus vaccine boosted markets and stoked hopes of a vaccine by the end of this year,

from Yahoo Finance https://ift.tt/2Wo90Dc